Investigational drug · Phase 3
Hexaxim
Also called: Hexaxim Vaccine, DTaP-IPV-Hib-HepB vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
10
Any phase or sponsor naming "Hexaxim"
First trial start
2023
Mar 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Hexaxim", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Immunization
- Meningococcal Immunisation
- Healthy Volunteers
Largest trials
Live from ClinicalTrials.gov: studies naming "Hexaxim" as an intervention, largest first.
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgePivotal-lookingActive, not recruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06736041 · 1,714 participants · Start Dec 18, 2024 · Primary completion May 17, 2027
Drug: PCV21 vaccine; Prevnar 20 vaccine and 5 more · For: Pneumococcal Immunization
Sites: Glendale, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 112 sites in all
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT05794230 · 1,528 participants · Start Mar 27, 2023 · Primary completion Nov 15, 2025
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine and 13 more · For: Meningococcal Immunisation; Healthy Volunteers
Sites: Chennai, India; Hyderabad, India; Kanpur, India · 15 sites in all
- Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.Pivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07941622 · 720 participants (planned) · Start Dec 28, 2026 · Primary completion Apr 27, 2028
Drug: DTaP-IPV-HB-PRP~T combined vaccine; DTaP-IPV//PRP~T combined vaccine and 1 more · For: Haemophilus Influenzae Type b Immunisation; Hepatitis B Immunisation; Polio Immunization and 4 more
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06793826 · 713 participants · Start Jan 17, 2025 · Primary completion Jan 15, 2026
Drug: DTaP-IPV-Hep B-PRP-T combined vaccine · For: Hepatitis B; Haemophilus Influenzae Type b Immunisation
Sites: Cheonan, South Korea; Seoul, South Korea
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02428491 · 354 participants · Start Apr 20, 2015 · Primary completion Jan 11, 2017
Drug: Hexaxim® · For: Diphtheria; Tetanus; Pertussis and 3 more
Sites: Thái Bình, Vietnam
- Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgePivotal-lookingStatus unknown
LG ChemIndustry
NCT06618196 · 336 participants (planned) · Start Oct 2, 2024 · Primary completion Jun 30, 2025
Drug: LR20062; DTaP-HepB-IPV-Hib vaccine · For: Diphtheria; Tetanus; Pertussis and 3 more
- Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at BirthPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT01948193 · 177 participants · Start Feb 2014 · Primary completion Dec 2014
Drug: Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine · For: Diphtheria; Tetanus; Whooping Cough and 3 more
Sites: Ludhiana, India; Pune, India
- Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.Pivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02697474 · 150 participants · Start Feb 2016 · Primary completion Jun 2016
Drug: Euvax B®: Hepatitis B vaccine; Euvax B®: Hepatitis B vaccine · For: Hepatitis B
Sites: Bangkok, Thailand; Khon Kaen, Thailand
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02610348 · 122 participants · Start Nov 2015 · Primary completion Dec 2015
Drug: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines; DTaP-HB-IPV and Pneumococcal polysaccharide vaccines · For: Hepatitis B
Sites: Bangkok, Thailand; Khon Kaen, Thailand
- DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02817451 · 53 participants · Start Jul 14, 2016 · Primary completion Feb 22, 2019
Drug: Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine; Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine · For: Diphtheria; Tetanus; Pertussis and 3 more
Sites: Soweto, South Africa
Newest research
PubMed records naming it or its code names, newest first.
- Inequalities in uptake of childhood vaccination in England, 2019-23: longitudinal study.
Flatt A, Vivancos R, French N, et al. · BMJ 2024
- DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure.
Boisnard F, Manson C, Serradell L, et al. · Expert Rev Vaccines 2023
- A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients.
Dakin A, Borrow R, Arkwright PD · Expert Rev Vaccines 2023
- Economic impact of switching from partially combined vaccine "Pentaxim® and hepatitis B" to fully combined vaccine "Hexaxim®" in the Malaysian National Immunization Program.
Aljunid SM, Al Bashir L, Ismail AB, et al. · BMC Health Serv Res 2022
- Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization.
Romero M, Góngora DS, Caicedo ML, et al. · Value Health Reg Issues 2021
- Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants.
Cho HK, Park SE, Kim YJ, et al. · Clin Exp Pediatr 2021
Also in development for Pneumococcal Immunization
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- M-M-R II vaccinePhase 33 trials
Sanofi · Pneumococcal Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.